Case study of primary imatinib resistance and correlation of BCR-ABL multiple mutations in chronic myeloid leukemia

By Iqbal Zafar   Siddiqui Rubina T   Qureshi Javed A   Khalid Ahmad M  

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 249-254

Future Medicine

Access to resources Recommend Favorite

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

By Razga Filip   Jurcek Tomas   Zackova Daniela   Dvorakova Dana   Toskova Martina   Jeziskova Ivana   Mayer Jiri   Racil Zdenek  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

BCR-ABL1⁺ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1^- Subclone as a Cause of Refractory Disease with Nilotinib Treatment

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 237-241

Karger

Access to resources Recommend Favorite

Molecular characterization and follow‐up of five CML patients with new BCR–ABL1 fusion transcripts

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 10, 2015-10 ,pp. : 595-605

John Wiley & Sons Inc

Access to resources Recommend Favorite

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 282-287

John Wiley & Sons Inc

Access to resources Recommend Favorite